A phase 2a, randomized, double-blind, placebocontrolled, single ascending-dose study to evaluate the safety and efficacy of naldemedine in patients with chronic noncancer pain and opioid-induced bowel dysfunction

Authors
Category Primary study
JournalJournal of Pain
Year 2016
This article has no abstract
Epistemonikos ID: 4abd8fd00ded4503b0b38523abd52f3413b15639
First added on: Feb 07, 2025